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with 358 who had at least one adverse event. Considering the
baseline characteristics, event-free patients were younger (54 vs. 61
years, p  0.0001), had a lower functional class (New York Heart
Association functional class I to II 97% vs. 87%, p  0.003), and
had a higher ejection fraction (32% vs. 29%, p  0.002) at
randomization. Event-free patients were also more likely to receive
in-trial enalapril therapy than placebo (38 [62%] vs. 173 [48%],
p  0.04).
Our data indicated that early enalapril therapy reduced death
and serious CV morbid events at 15 years in the Belgian SOLVD
cohort. Specifically, at the end of this extended follow-up, a
significant risk reduction in mortality was observed among patients
treated early with enalapril compared with placebo, confirming our
previous findings in the X-SOLVD trial. One mechanism that
could explain these clinical benefits is the beneficial effect of
enalapril on left ventricular remodeling and diastolic properties (5).
Furthermore, prevention of early nonfatal cardiac ischemic events
by enalapril during in-trial treatment (3) may lead to a late benefit
in mortality. The original SOLVD data showed that enalapril
reduced the incidence of cardiac ischemic events. The present
study extended this finding by showing that the risk of death or
nonfatal cardiac ischemic events remained significantly lower in
the early enalapril group than in the delayed group. This suggests
that earlier treatment initiation may confer long-term protection
against atherosclerotic complications by a sustained beneficial
effect on plaque stability and vascular remodeling (3,6). Moreover,
our data suggested that on the event-free patients, middle-aged
asymptomatic subjects derived the most protection from early
enalapril therapy. This observation confirms the need to initiate
enalapril without delay in patients with reduced ejection fractions,
even in the absence of symptoms. However, we could not exclude
that genetic variations might also explain this excellent long-term
evolution.
In conclusion, in the 15-year follow-up of the Belgian SOLVD
cohort, early enalapril therapy prevented late deaths and serious
CV morbid events beyond the original trial period. Our data also
refuted the suggestion that ACE inhibitors in patients with
asymptomatic or minimally symptomatic ventricular dysfunction
would not confer any long-term benefit except for masking the
development of heart failure. Our study showed the importance of
starting ACE inhibitor therapy as early as possible in patients with
left ventricular systolic dysfunction to avoid any delay resulting in
any significant loss of benefits years later.
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Short QT Interval and Atrial Fibrillation in Patients Without Structural Heart Disease
To the Editor: The short QT syndrome is a newly described
clinical entity characterized by the presence of a short QT interval
associated with cardiac tachyarrhythmias in otherwise healthy
individuals. A genetic basis has been identified linking the disease
to mutations in KCNH2 in the familial forms and a mutation in
KCNQ1 in a sporadic form of the disease (1). The description of
a novel, de novo gain of function mutation in KCNQ1, responsible
for atrial fibrillation (AF) and short QT syndrome in utero,
indicates that gain of function mutations in KCNQ1 channels can
shorten the duration of both ventricular and atrial action potentials
(2), which could account for the high incidence of AF in patients
with short QT syndrome (3). Atrial fibrillation can occur in the
Figure 1. Kaplan-Meier mortality curves during the post-trial period
between patients randomized to enalapril and to placebo. The data showed
that the benefit in the enalapril group was apparent within the first year
after trial close-out and persisted for the entire duration of the extended
follow-up (Wilcoxon p  0.01).
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absence of detectable organic heart disease, so-called “lone AF,” in
about 30% of cases (4). Because the pathophysiology of lone AF
remains poorly defined, we speculated that mechanisms underlying
the high incidence of AF in short QT syndrome might also be
responsible for the development of AF in the absence of structural
heart disease. To test this hypothesis we examined QT interval
duration in 165 consecutive healthy subjects presenting with an
episode of AF (AF group). The control group included 165 age-
and gender-matched subjects without any evidence of arrhythmia
on a standard electrocardiogram (ECG).
Data on the AF group were collected at the hospital emergency
department, and data on the control group were obtained in
healthy individuals at the time of routine outpatient check-up as a
part of national cardiovascular disease prevention program. Sub-
jects treated with type I or type III antiarrhythmic drugs, anti-
depressive drugs, antihistamines, or macrolide antibiotics were not
included in the study.
In all subjects, we recorded resting 12-lead ECGs at a paper
speed of 25 mm/s on a Marquette Resting ECG recorder (Mar-
quette Electronics Inc., Milwaukee, Wisconsin). With calipers on
printed ECGs, the QT interval of each lead was measured from
the beginning of the QRS complex to the visual return of the
T-wave to the isoelectric line. When the T-wave was interrupted
by the U-wave, the end of the T-wave was defined as the nadir
between the T-wave and the U-wave. When the nadir was not
clearly visible or the maximal T-wave amplitude did not exceed
0.25 mV, the ECG lead was excluded. All the QT interval
measurements were performed with patients in sinus rhythm.
Heart rate correction was done with the Bazett formula, and QTc
interval duration was defined as the mean duration of all QTc
intervals measured.
Differences between the AF and control groups were analyzed
with 1-factor analysis of variance (ANOVA). Comparisons of
categorical variables were made with a chi-square test. Both forward
and backward stepwise linear regression analyses were used to
identify predictive multivariate models. A p value  0.05 was
considered significant.
The two groups did not differ significantly with regard to age
(62  10 years in AF group vs. 61  9 years in control group, p 
0.67), gender (male: 67% in AF group vs. 66% in control group,
p  0.90), history of hypertension (72% in AF group vs. 71% in
control group, p  0.80), or diabetes (10% in AF group vs. 8% in
control group, p  0.76). Similarly, we found no inter-group
differences in left ventricular ejection fraction (58.8  7.9% in AF
group vs. 61.1 10.3% in control group, p 0.80), dimensions of
the left atrium (4.1  1.2 cm in AF group vs. 4.0  1.3 in control
group, p  0.69), resting heart rate (83  23 beats/min in AF
group vs. 78  25 beats/min in control group, p  0.62), or QRS
complex duration (94  15 ms in AF group vs. 91  21 ms in
control group, p  0.54). No family history of premature sudden
death was found in any of the groups; the history of syncope was
present in 7% of patients from the AF group and in 4% of the
control group (p  0.24). The QTc interval of patients in the AF
group, however, was significantly shorter compared with QTc
interval in the control group (Fig. 1). Short QTc interval (400
ms) was an independent predictor of AF occurrence in the
multivariate analysis (p  0.002), whereas hypertension, diabetes,
decreased left ventricular ejection fraction (60%), and increased
left atrial size (4 cm) were not.
Our findings demonstrate that even in the absence of genetically
identifiable chanellopathies, patients with AF and no structural
heart disease have significantly shorter QT intervals than their age-
and gender-matched healthy counterparts. We therefore speculate
that pathophysiological mechanisms that lead to shortening of QT
interval (even of mild degree) might also play an important role in
genesis of AF in structurally normal hearts. Action potential
duration of ventricular myocardium is largely determined by the
activation of delayed rectifier potassium current (IKs): with the
loss-of-function mutation of IKs, the ventricular action potential is
prolonged (clinically long QT syndrome); and in the gain-of-
function mutation of IKs, it is shortened (clinically short QT
syndrome) (5). The resulting enhancement of transmural disper-
sion of myocardial repolarization together with heterogeneous
reduction in action potential duration creates a vulnerable window
for ventricular arrhythmias. Similarly, the potassium current in
human atrium shows kinetically distinguishable rapid and slow
components, which might be of principal importance in determin-
ing atrial repolarization and its regulation by the autonomic
nervous system and antiarrhythmic drugs (6). Therefore, the
association of AF and short QT interval in our study might be
partially explained by the alterations in IKs in both atrial and
ventricular myocytes. Further studies are needed to better define
the underlying pathophysiology and to investigate whether atrial
and ventricular arrhythmias are generated by similar electrophys-
iological mechanisms.
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Association of Pulsus Paradoxus With Obesity in Normal Volunteers
To the Editor: First termed by Adolf Kussmaul in an 1873
manuscript (1), the physical finding of pulsus paradoxus (PP) has
been described in numerous clinical situations, including constric-
tive pericarditis, cardiac tamponade, acute pulmonary hyperten-
sion, severe asthma, tension pneumothorax, and exacerbations of
chronic obstructive pulmonary disease (2). Originally described as
the disappearance of the palpated pulse during inspiration in the
setting of pericardial constriction, PP has more recently been
defined as a drop in systolic blood pressure (SBP) of 10 mm Hg
with inspiration. This classic physical finding is discussed at all
levels of medical training and is frequently used in clinical
medicine.
Obesity, defined as a body mass index (BMI) 30 kg/m2, is a
condition affecting over 30% of the U.S. population and is a global
epidemic (3). In obese patients, the compressive effects of increased
abdominal girth on the chest wall and diaphragm might increase
the work of breathing. We hypothesized that this exaggerated
respiratory effort might lead to PP in otherwise healthy obese
patients. Accordingly, we performed a prospective study to inves-
tigate the relationship between obesity and PP in patients under-
going elective cardiac catheterization.
Adult patients presenting for elective cardiac catheterization
were prospectively studied for the presence of PP. These were
patients with no known or suspected pericardial or pulmonary
diseases by complete history and chart review. Inclusion criteria
were: adult patients undergoing elective cardiac catheterization
who consented to participate in the study. Exclusion criteria were:
1) any known cause of PP, to include history of chronic obstructive
pulmonary disease, active or chronic pericardial diseases, active
asthma exacerbation, or use of any bronchodilating medications;
2) urgent need for catheterization (e.g., ST-segment elevation
myocardial infarction or hemodynamic instability); 3) right ven-
tricular infarction; 4) recent pulmonary embolism; 5) pregnancy; or
6) decompensated heart failure.
On the day of cardiac catheterization, a physical examination
was performed to exclude the presence of pulmonary or pericardial
disease. Height, weight, and body circumferences at the umbilical
and xiphoid levels were measured. A limited two-dimensional
transthoracic echocardiogram was performed to exclude occult
pericardial effusion and to assess for structural changes consistent
with constrictive pericardial disease. No patient was noted to have
occult pericardial effusion or significant structural enlargement of
the heart chambers. Pulsus paradoxus was first measured non-
invasively with sphygmomanometry and then invasively assessed
within 1 h at the time of cardiac catheterization. By convention, a
PP value of 10 mm Hg was considered abnormal.
Table 1. Demographic Characteristics of the 101 Study Participants
Non-Obese
(n  64)
Obese
(n  37) p Value
Age (yrs) 58  12 57  13 0.69
Gender, male (%) 52 (81.3%) 26 (70.3%) 0.23
Smoking history, n (%)
Active 14 (23%) 9 (25%) 0.68
Prior 24 (39.3%) 11 (30.6%)
None 23 (37.7%) 16 (44.4%)
Coronary disease, n (%)
None 26 (40.6%) 20 (54%) 0.107
1-vessel 8 (12.5%) 8 (21.6%)
2-vessel 16 (25%) 3 (8.1%)
3-vessel 14 (21.9%) 6 (16.2%)
Blood pressure (mm Hg)
Systolic 144.6  23.3 142.9  20.5 0.72
Diastolic 77.5  10.5 78.4  9.6 0.65
Mean 104.2  12.9 104.5  11.7 0.91
Left ventricular end-diastolic pressure
(mm Hg), n  59
18.1  4.4 (n  35) 20.2  5.1 (n  24) 0.10
Pulse pressure (mm Hg) 67.1  23.1 64.5  18.9 0.56
Height (cm) 175.2  4.1 173.9  5.6 0.54
Weight (kg) 81.8  5.7 105.0  8.0 0.001
BMI (kg/m2) 26.6  1.4 34.7  2.2 0.001
Girth, umbilical (cm) 103.6  4.8 122.2  6.1 0.001
Girth, xiphoid (cm) 101.8  8.9 113.5  9.4 0.001
Values displayed as mean  standard deviation.
BMI  body mass index.
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